Mavenclad resulted in stable/better cognitive function and stable employment status over 2 years in highly active relapsing ...
The Phase II trial enrolled 129 participants, of whom 94% had relapsing remitting multiple sclerosis, and 6% had secondary ...
Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...
The experimental drug fenebrutinib worked better than Aubagio, an approved therapy, for reducing relapse rates in MS, new ...
A woman in her 50s with genetically confirmed Huntington’s disease presented with right-sided arm sensory symptoms that ...
WEST PALM BEACH, Fla. -- The investigational oral Bruton's tyrosine kinase (BTK) inhibitor evobrutinib failed to distinguish itself from teriflunomide (Aubagio) in two phase III trials of relapsing ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...
Disability accumulation may occur independently of relapses for some patients in the early phase of relapsing-remitting multiple sclerosis (MS), according to new research. Approximately 61% of ...
Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results